| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA062930 |
| P8608 | Fatcat ID | release_tw2yipxrqjcplgquvae7ztjd3y |
| P698 | PubMed publication ID | 17065638 |
| P2093 | author name string | Marshall R Posner | |
| Lisa A Cavacini | |||
| A Razzaque Ahmed | |||
| Zachary Spigelman | |||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pemphigus vulgaris | Q3899001 |
| Pemphigus vulgaris | Q10622783 | ||
| rituximab | Q412323 | ||
| P304 | page(s) | 1772-1779 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin | |
| P478 | volume | 355 |
| Q45885198 | Acquired haemophilia treated successfully with rituximab in a patient with pemphigus vulgaris |
| Q50889172 | Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. |
| Q36857368 | Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients |
| Q47977153 | Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up. |
| Q37246934 | Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: a paradigm of human autoimmunity. |
| Q33924642 | Altered B cell signalling in autoimmunity |
| Q38245848 | An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab |
| Q35953366 | Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection |
| Q40180170 | Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease. |
| Q33921744 | Anti-cytokine autoantibodies explain some chronic mucocutaneous candidiasis |
| Q37812457 | Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms |
| Q41846224 | Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis |
| Q33747588 | Autoimmunity as a predisposition for infectious diseases |
| Q38179053 | Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris |
| Q37308252 | B cells and immunological tolerance. |
| Q56897632 | B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses |
| Q37369906 | B-cell-directed therapy for inflammatory skin diseases |
| Q37993932 | Biologics in oral medicine: principles of use and practical considerations |
| Q37999475 | Biologics in oral medicine: ulcerative disorders |
| Q39906630 | Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases |
| Q33919417 | Biosimilars in pemphigus vulgaris |
| Q49382688 | British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. |
| Q37626123 | Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. |
| Q64996575 | Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology. |
| Q53126755 | Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up. |
| Q36134951 | Cutaneous manifestations of systemic lupus erythematosus. |
| Q38072118 | Desmoglein 3, its pathogenecity and a possibility for therapeutic target in pemphigus vulgaris. |
| Q26771723 | Dyslipidemia in Dermatological Disorders |
| Q37230344 | Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007 |
| Q34241174 | Efficacy and safety of rituximab treatment in Indian pemphigus patients. |
| Q55433740 | Emerging treatment options for the management of pemphigus vulgaris. |
| Q38078021 | Epidermolysis bullosa acquisita |
| Q90423621 | Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial |
| Q38876705 | First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial |
| Q35531873 | Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates |
| Q37532013 | High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases |
| Q38644346 | Immune response in pemphigus and beyond: progresses and emerging concepts. |
| Q82770082 | Immunoadsorption in the treatment of pemphigus |
| Q36140831 | Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus |
| Q37933423 | Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update |
| Q37873722 | Intravenous immunoglobulin therapy in rheumatic diseases |
| Q37773248 | Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science |
| Q38218539 | Japanese guidelines for the management of pemphigus |
| Q38201755 | Kaposi's sarcoma in a patient with pemphigus vulgaris |
| Q54526312 | Life-threatening course of pemphigus vulgaris complicated by sepsis caused by azathioprine-induced bone marrow suppression, successfully managed with combination therapy. |
| Q37833902 | Long-lived autoreactive plasma cells drive persistent autoimmune inflammation |
| Q37394846 | Long-term efficacy of biologics in dermatology |
| Q51397179 | Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients. |
| Q50910869 | Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. |
| Q33393434 | Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia |
| Q26747092 | Management of Pemphigus Vulgaris |
| Q35173849 | Management of pemphigus |
| Q26778895 | Management of pemphigus vulgaris: challenges and solutions |
| Q38747187 | Mechanisms of Disease: Pemphigus and Bullous Pemphigoid. |
| Q48142572 | Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis. |
| Q92063774 | Modified Rheumatoid Arthritis Protocol for Rituximab in Pemphigus: A Retrospective Case Series |
| Q36807468 | Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. |
| Q37642875 | Non-psoriatic dermatologic uses of monoclonal antibody therapy |
| Q34087599 | Novel applications of Rituximab in dermatological disorders |
| Q58861268 | Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin |
| Q37598882 | Novel therapies for pemphigus vulgaris: an overview |
| Q28245986 | Ocrelizumab: a step forward in the evolution of B-cell therapy |
| Q64095262 | Ocular Manifestations and Management of Autoimmune Bullous Diseases |
| Q37940584 | Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis, and current management |
| Q34135478 | Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment |
| Q56603745 | Pemphigus |
| Q93192667 | Pemphigus |
| Q37937040 | Pemphigus autoimmunity: hypotheses and realities |
| Q92312713 | Pemphigus vulgaris |
| Q38345404 | Pemphigus vulgaris: an evidence-based treatment update |
| Q91782600 | Pemphigus: Current and Future Therapeutic Strategies |
| Q47219879 | Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. |
| Q37591473 | Pemphigus: a brief review |
| Q34964558 | Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years |
| Q42141964 | Practical issues for clinicians using high-dose intravenous immunoglobulin |
| Q38154934 | Preliminary analysis of mortality associated with rituximab use in autoimmune diseases |
| Q58482127 | Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus |
| Q34655158 | Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases |
| Q37059099 | Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases |
| Q33971785 | Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses |
| Q64904663 | Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin. |
| Q40097140 | Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. |
| Q48204330 | Rituximab and short-course prednisone as the new gold standard for new-onset pemphigus vulgaris and pemphigus foliaceus |
| Q54643008 | Rituximab as first-line treatment of pemphigus. |
| Q81478296 | Rituximab exerts a dual effect in pemphigus vulgaris |
| Q36751954 | Rituximab for autoimmune blistering diseases: recent studies, new insights. |
| Q49866575 | Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. |
| Q79819158 | Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion |
| Q59810234 | Rituximab in Pemphigus: Road Covered and Challenges Ahead |
| Q50075561 | Rituximab in pemphigus |
| Q35683952 | Rituximab in severe skin diseases: target, disease, and dose |
| Q36434853 | Rituximab in the treatment of pemphigus vulgaris |
| Q37083395 | Rituximab in treatment-resistant autoimmune blistering skin disorders |
| Q51771325 | Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. |
| Q33378620 | Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks |
| Q37620483 | Rituximab therapy in pemphigus and other autoantibody-mediated diseases |
| Q35169725 | Rituximab therapy of recalcitrant bullous dermatoses. |
| Q53727241 | Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs. |
| Q37781697 | Rituximab: a review of dermatological applications |
| Q33798060 | Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab |
| Q35557832 | Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). |
| Q37157777 | Seeking approval: present and future therapies for pemphigus vulgaris |
| Q37677416 | Setting the target for pemphigus vulgaris therapy |
| Q33737974 | Shifting Focus in the Therapeutics of Immunobullous Disease |
| Q58864656 | Shortage of human intravenous immunoglobulin—reasons and possible solutions |
| Q50786186 | Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. |
| Q42217718 | Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris |
| Q55234556 | Targeting B Cells and Plasma Cells in Autoimmune Diseases. |
| Q41862512 | The case for case reports |
| Q36700065 | The desmosome and pemphigus |
| Q38384497 | The emerging role of rituximab in autoimmune blistering diseases |
| Q58583171 | The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy |
| Q38191339 | The management of pemphigus vulgaris in a burn intensive care unit: a case report and treatment review |
| Q38824186 | The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking? |
| Q37397567 | The role of case reports in evidence-based practice, with suggestions for improving their reporting |
| Q36986054 | The use of i.v. IG therapy in dermatology |
| Q37552017 | Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases |
| Q33385389 | Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders |
| Q37552019 | Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy |
| Q46758038 | Treatment failure with rituximab in a patient with pemphigus vulgaris |
| Q43472409 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience |
| Q45007774 | Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication |
| Q46742155 | Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris |
| Q37984131 | Urban legends: pemphigus vulgaris. |
| Q36839957 | What's new in blistering disorders? |
| Q37131029 | What's new in dermatologic therapy |
| Q33357138 | What's new in dermatological therapy? |
| Q93572541 | What's new in the other general journals |
| Q81944280 | [B-cell-depleting antibodies in skin diseases] |
| Q80516806 | [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] |
| Q45964401 | [Optimizing therapy in patients with severe autoimmune blistering skin diseases]. |
| Q84781242 | [Orogenital and conjunctival involvement in hereditary and autoimmune blistering diseases] |
| Q85690153 | [Pemphigus. Model disease for targeted therapy] |
| Q81465472 | [Practical management of the most common autoimmune bullous diseases] |
| Q54650521 | [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases]. |
| Q80426565 | [Rituximab: mabthera] |
| Q83200982 | [Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases] |
| Q54102494 | [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders]. |
| Q81477489 | [[Treatment of therapy resistant pemphigus vulgaris with rituximab and immunoglobulins] |
Search more.